Mainz Biomed (NASDAQ:MYNZ) Sees Significant Decrease in Short Interest

Mainz Biomed (NASDAQ:MYNZ) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,700,000 shares, a decrease of 25.1% from the September 30th total of 2,270,000 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 0.9 days. Currently, 9.7% of the company’s stock are sold short.

Mainz Biomed Trading Down 6.9 %

Shares of MYNZ traded down $0.02 during midday trading on Friday, hitting $0.26. 2,355,691 shares of the company’s stock traded hands, compared to its average volume of 869,824. The stock has a market capitalization of $3.11 million, a price-to-earnings ratio of -0.16 and a beta of 0.09. Mainz Biomed has a 1 year low of $0.19 and a 1 year high of $3.39. The firm’s fifty day moving average is $0.31 and its 200-day moving average is $0.48.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.